-
EP3875484
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3875484
| EP3875484 - CLL1-TARGETING ANTIBODY AND APPLICATION THEREOF [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 19.05.2023 Database last updated on 09.09.2024 | |
| Former | Request for examination was made Status updated on 06.08.2021 | ||
| Former | The international publication has been made Status updated on 02.05.2020 | Most recent event Tooltip | 19.05.2023 | Application deemed to be withdrawn | published on 21.06.2023 [2023/25] | Applicant(s) | For all designated states CRAGE medical Co., Limited RM12, 20/F, Ho King Comm CTR 2-16 FaYuen ST Mongkok Kowloon Hong Kong / CN | [2022/17] |
| Former [2021/36] | For all designated states CAFA THERAPEUTICS LIMITED 2/3 Exchange Place, IFSC Dublin D01 AE27 / IE | Inventor(s) | 01 /
LI, Zonghai Building 12, No. 388 Yindu Road, Xuhui District Shanghai 200231 / CN | 02 /
WANG, Peng Building 12, No. 388 Yindu Road, Xuhui District Shanghai 200231 / CN | 03 /
WANG, Huamao Building 12, No. 388 Yindu Road, Xuhui District Shanghai 200231 / CN | [2021/36] | Representative(s) | dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB Deichmannhaus am Dom Bahnhofsvorplatz 1 50667 Köln / DE | [2021/36] | Application number, filing date | 19877290.7 | 28.10.2019 | [2021/36] | WO2019CN113767 | Priority number, date | CN201811260687 | 26.10.2018 Original published format: CN201811260687 | [2021/36] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020083406 | Date: | 30.04.2020 | Language: | ZH | [2020/18] | Type: | A1 Application with search report | No.: | EP3875484 | Date: | 08.09.2021 | Language: | EN | [2021/36] | Search report(s) | International search report - published on: | CN | 30.04.2020 | (Supplementary) European search report - dispatched on: | EP | 17.06.2022 | Classification | IPC: | C07K16/28, C12N15/62, C12N5/10, A61K39/395, A61P35/02 | [2021/36] | CPC: |
C07K14/7051 (EP,US);
C07K16/2851 (EP,KR,US);
A61K2239/48 (EP,US);
A61K39/395 (KR);
A61K39/4611 (EP,US);
A61K39/4631 (EP,US);
A61K39/464402 (EP,US);
A61K47/6849 (US);
A61P35/00 (KR,US);
A61P35/02 (EP);
C07K14/705 (KR);
C07K14/70517 (US);
C07K14/70521 (US);
C07K14/70578 (US);
C12N5/0636 (EP,KR,US);
A61K2039/505 (EP,KR,US);
A61K2039/804 (EP);
C07K2317/21 (US);
C07K2317/56 (EP);
C07K2317/565 (EP,KR,US);
C07K2317/622 (EP,KR,US);
C07K2317/73 (US);
C07K2317/92 (EP,KR,US);
C07K2319/02 (US);
C07K2319/03 (EP,US);
C07K2319/30 (KR,US);
C07K2319/33 (US);
C12N2510/00 (KR)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/36] | Title | German: | GEGEN CLL1 GERICHTETER ANTIKÖRPER UND VERWENDUNG DAVON | [2021/36] | English: | CLL1-TARGETING ANTIBODY AND APPLICATION THEREOF | [2021/36] | French: | ANTICORPS CIBLANT CLL1 ET SON UTILISATION | [2021/36] | Entry into regional phase | 26.05.2021 | Translation filed | 26.05.2021 | National basic fee paid | 26.05.2021 | Search fee paid | 26.05.2021 | Designation fee(s) paid | 26.05.2021 | Examination fee paid | Examination procedure | 26.05.2021 | Examination requested [2021/36] | 27.12.2021 | Amendment by applicant (claims and/or description) | 17.01.2023 | Application deemed to be withdrawn, date of legal effect [2023/25] | 07.02.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2023/25] | Fees paid | Renewal fee | 25.10.2021 | Renewal fee patent year 03 | 25.10.2022 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI]WO2013169625 (CELLERANT THERAPEUTICS INC [US]); | [XI]WO2016040868 (GENENTECH INC [US]) |